Technology ID
TAB-2664
T24 Antigen for Diagnosing or Treating Taenia solium Cysticercosis
E-Numbers
E-237-2013-0
Lead Inventor
Hancock, Kathy (CDC)
Co-Inventors
Williams, Fatima (CDC)
Yushak, Melinda (CDC)
Pattabhi, Sowmya (CDC)
Tsang, Victor (CDC)
Applications
Vaccines
Therapeutics
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
- Early-stage
- In vitro data available
Lead IC
CDC
ICs
CDC
In order to develop a simple detection assay for field use, CDC researchers cloned and sequenced the Taenia solium T24 diagnostic protein. The T24 sequences can be used to detect and diagnose T. solium infection or can be formulated into a pharmaceutical composition. T. solium is a species of tapeworm. Intestinal infection with T. solium is referred to as taeniasis. Many taeniasis infections are asymptomatic but may be characterized by insomnia, anorexia, abdominal pain and weight loss. Cysticercosis infection, which can be fatal, may develop if T. solium larvae migrate out of the intestine and form cysticerci in various body tissues. This technology may be used to develop a diagnostic, vaccine, or therapeutic for infection related to T. solium.
Commercial Applications
- Vaccine or therapeutic for taeniasis or cysticercosis resulting from T. solium infection
- Diagnosis of T. solium infection
- Zoonotic disease research and surveillance
- Public health monitoring programs
- Livestock health and food-source monitoring
Competitive Advantages
- Rapid, accurate, sensitive, and safe compared to current radiologic and biopsy diagnostic methods
- Easy-to-use diagnostic kit that doesn't require abnormal temperatures or specialized equipment
- Can be developed for serologic and/or nucleic acid diagnostics
- Cost-effective; useful for developing countries
Licensing Contact: